# Integra Lifesciences Holdings (IART) — News

IART · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/iart/news

## Recent headlines

- [Integra provides Delamar project update: Detailed engineering, permitting, procurement and state of good repairs work advancing in line with plan, appoints GenCap as project financing advisor](https://www.ainvest.com/news/integra-delamar-project-update-detailed-engineering-permitting-procurement-state-good-repairs-work-advancing-line-plan-appoints-gencap-project-financing-advisor-2610) — AInvest Wire, Oct 13, 2026
- [Integra announces pricing of senior secured notes](https://www.ainvest.com/news/integra-announces-pricing-senior-secured-notes-2610) — AInvest Wire, Oct 9, 2026
  Integra LifeSciences has announced the pricing of its senior secured notes as part of its ongoing refinancing activities. The company is issuing $600 million in senior secured notes, which are set to mature in 2030. These notes are part of a broader refinancing strategy aimed at optimizing the…
- [Moody's Ratings assigns B2 rating to Integra's sr. secured notes; outlook stable](https://www.ainvest.com/news/moody-ratings-assigns-b2-rating-integra-sr-secured-notes-outlook-stable-2610) — AInvest Wire, Oct 7, 2026
  Moody’s Investors Service has assigned a B2 rating to Integra’s senior secured notes, with a stable outlook, reflecting the company’s credit profile and new debt issuance terms . The B2 rating indicates a higher level of credit risk but suggests that the notes are still considered speculative with…
- [Integra Life Sciences Holdings Corporation: BMO cuts target price to $15 from $18](https://www.ainvest.com/news/integra-life-sciences-holdings-corporation-bmo-cuts-target-price-15-18-2610) — AInvest Wire, Oct 5, 2026
  BMO Capital has revised its price target for Integra Life Sciences Holdings Corporation (NYSE: IART), reducing it to $15 from $18, reflecting a reassessment of the company’s near-term outlook. The adjustment follows ongoing market analysis and evolving expectations regarding the medical device…
- [IART sees FY rev.$1.63B to $1.65B, saw $1.65B to $1.70B](https://www.ainvest.com/news/iart-sees-fy-rev-1-63b-1-65b-1-65b-1-70b-2610-14) — AInvest Wire, Oct 2, 2026
  IART reported its fiscal year revenue forecast in the range of $1.63 billion to $1.65 billion, slightly below the previously estimated range of $1.65 billion to $1.70 billion [1]. The updated guidance reflects adjustments based on performance across the reporting period. The company attributed the…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).